EGFR and breast carcinoma: The findings collected from this study supported that miR-182-5p delivered by breast cancer cell-derived EVs aggravated the development of breast cancer, which was related to its inhibition on the CMTM7 expression and activation on the EGFR/AKT signaling pathway.